Preliminary Q2 Sales Top $90M, More Than Double Year-Ago
STAA sits 86% above its 52-week low of $15.585.
Summary
STAAR Surgical pre-announced Q2 2026 net sales exceeding $90 million, more than double the $44.3 million from Q2 2025. The strong performance was driven by sequential growth in China, solid Asia-Pacific results, and double-digit growth in the Americas. EMEA sales dipped slightly due to Middle East turmoil, declining by a low-single-digit percentage, but the region grew double-digits excluding that area. Co-CEO Warren Foust noted ERP implementation challenges during the quarter, but the team still delivered. This follows a record Q1 with $93.5 million in sales and a return to profitability. The full Q2 report is expected August 12, which will provide profit and margin details.
At the time of this announcement, STAA was trading at $28.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $15.59 to $35.87. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.